Press release
Investigation announced for Long-Term Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN)
An investigation on behalf of current long term investors in Acelyrin, Inc. (NASDAQ: SLRN) shares.
Investors who are current long term investors in Acelyrin, Inc. (NASDAQ: SLRN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SLRN stocks follows a lawsuit filed against Acelyrin, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SLRN stocks, concerns whether certain Acelyrin, Inc. officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that izokibep was less effective in treating HS than Defendants had led investors to believe, that accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects, that as a result, Acelyrin also overstated the Company's business prospects post-IPO, and thatas a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN) here
News-ID: 3494998 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Acelyrin
Uveitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight …
DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Uveitis Market Forecast
https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Uveitis…
Thyroid Eye Disease Market Top Players - Horizon Therapeutics, Viridian Therapeu …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Thyroid Eye Disease Market - (By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Thyroid Eye Disease Market is valued at US$ 2.15 billion in 2023, and it is expected to reach US$…
Hidradenitis Suppurativa Treatment Market 2034: FDA Approvals, Clinical trials, …
(Albany, USA) DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast
https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
Deadline on Jan. 16th coming up in Lawsuit filed for Investors in shares of Acel …
A deadline is coming up on January 16, 2024 in the lawsuit filed for certain investors of Acelyrin, Inc. (NASDAQ: SLRN) over alleged securities laws violations by Acelyrin, Inc. (NASDAQ: SLRN).
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and there are strict and short deadlines running. Deadline: January 16, 2024. NASDAQ: SLRN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According…
Lawsuit filed for Investors who lost money with shares of Acelyrin, Inc. (NASDAQ …
An investor, who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN), filed a lawsuit over alleged violations of Federal Securities Laws by Acelyrin, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2024. NASDAQ: SLRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Acelyrin, Inc.
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Acelyrin, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Agoura Hills, CA based…
